Multidisciplinary tumor board is associated with improved survival in patients with hepatocellular carcinoma after liver transplantation

Table 3 Patient outcomes

Outcomes	MDTB group (n = 117)	non-MDTB group (n = 276)	P value
Complications grade III/IV	24 (20.5)	71 (25.7)	0.304
Post-operative deaths	9 (7.7)	28 (10.1)	0.572
Tumor progression/MOF	2 (1.7)	10 (3.6)
Sepsis	3 (2.6)	9 (3.2)
ARDS	2 (1.7)	4 (1.4)
Sudden cardiac arrest	1 (0.8)	3 (1.1)
GVHD	1 (0.8)	2 (0.7)
Re-transplantation	12 (10.3)	23 (8.3)	0.563
Hepatic graft dysfunction	6 (5.1)	10 (3.6)
Cholestatic graft dysfunction	4 (3.4)	9 (3.3)
Hepatic artery thrombosis	2 (1.7)	4 (1.4)
Tumor recurrence	24 (20.8)	87 (31.5)	0.104
Liver only	8 (6.8)	26 (9.4)
Liver and other	7 (5.9)	24 (8.7)
Other	14 (11.9)	37 (13.4)
Recurrence time, months	28.7 ± 14.9	21.5 ± 10.3	< 0.001

Data are presented as n (%). ARDS: Acute respiratory distress syndrome; GVHD: Graft versus host disease; MDTB: Multidisciplinary tumor board; MOF: Multiple organ failure.